The Million Veteran Program: Strategies for Consent & Sample Collection Gerry Higgins, M.D., Ph.D. and the ‘Genomics Advisory Panel’ of OSEHRA.

Slides:



Advertisements
Similar presentations
FDA QS reg/CLIA Comparison: Overview
Advertisements

Genomic Medicine Pilot Demonstration Projects
Medicaid Division of Medicaid and Long-Term Care Department of Health and Human Services Managed Long-Term Services and Supports.
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
The Veterans Affairs Central Biorepository and MVP Highlights Mary T
1 The HIPAA Privacy Rule and Research This presentation will probably involve audience discussion, which will create action items. Use PowerPoint to keep.
The Consent Process: It’s More Than Just a Form A “10 Minute Training” Brought to you by Cyndi Long, MS, RD, CCRC CU Sports Medicine.
New Staff Orientation1 SURVEY AND CERTIFICATION 101 Tracey B. Mummert, MT (ASCP) Special Assistant CMSO, Survey and Certification Group.
Clinical Trials: Clinical Research Billing, MSP, MMSEA, and Other Issues Meant to Complicate Our Lives 2011 Corporate Council Meeting 17 February 2011.
Newborn Screening Overview Marie Mann, M.D., M.P.H. U.S. Department of Health and Human Services Health Resources and Services Administration Maternal.
LtCol Roger Gibson Office of the Assistant Secretary of Defense Health Affairs DoD/VA Clinical Practice Guideline Toward Improved Quality of Post-Deployment.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
FDA Panel Comments Adele Schneider, MD, FACMG Victor Center for the Prevention of Jewish Genetic Diseases, Director, Clinical Genetics Albert Einstein.
Documentation for Acute Care
Informed Consent and HIPAA Tim Noe Coordinating Center.
Unit 4: Monitoring Data Quality For HIV Case Surveillance Systems #6-0-1.
Burton Garten Indiana State Department of Health.
2 H. Westley Clark, M.D., J.D., M.P.H., CAS, FASAM Director Center for Substance Abuse Treatment Substance Abuse Mental Health Services Administration.
American Chiropractic Association Just Imagine...
William B Munier, MD, MBA, Director Center for Quality Improvement and Patient Safety Agency for Healthcare Research and Quality AHRQ Annual Conference.
Behavioral Health Coding that Works in Primary Care Mary Jean Mork, LCSW April 16 & 17, 2009.
CLIA COMPLIANCE. What is CLIA? In 1988 Congress turned its attention to deficiencies in the quality of services provided by the nation’s laboratories.
The University of Kansas Medical Center Shadow Experience Training.
CAHPS Overview Clinician & Group Surveys: Practical Options for Implementation and Use AHRQ ANNUAL MEETING SEPTEMBER 18, 2011 Christine Crofton, PhD CAHPS.
Paula Peyrani, MD Medical/Project Director, HIV Program at the 550 Clinic Assistant Director, Research Design and Development Clinical and Translational.
Community Feedback and Involvement in [Health Department’s] Proposed Data to Care Program [Name of Provider Session Date of Provider Session]
Introduction to US Health Care
Chapter 20 Patient Interview. 2 3 Learning Objectives  Define and spell key terms  Define the purpose and the key components of the patient interview.
Organization of the US Health Services System
TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.
DIVISION OF LICENSING & CERTIFICATION, BUREAU OF HEALTH SYSTEMS (BHS) - MDCH (517) Fax (517)
Joe Selby, MD MPH EBRI December 15, 2011 What Might Patient (Employee)- Centered Research Look Like?
Health Care Cost Database Presented by the Office of the Commissioner of Securities and Insurance January 2011.
Copyright ©2011 by Pearson Education, Inc. Upper Saddle River, New Jersey All rights reserved. Health Information Technology and Management Richard.
HIPAA UPDATES. HIPAA – KNOWING WHAT IT IS Health Information Portability and Accountability Act “HIPAA” - federal law giving patients certain privacy.
Anticipated FY2016 Appropriations Agency$ Million NIH200 Cancer70 Cohort130 FDA10 Office of the Natl Coord. for Health IT (ONC) 5 TOTAL215 Mission: To.
Revision Process for the PHS Guideline for Reducing HIV, HBV and HCV Transmission through Solid Organ Transplantation Matthew J. Kuehnert, M.D. Office.
Legal & Ethical Issues. Objectives At the completion of this session the participant will be able to: ◦ Describe the ethical principles associated with.
Understanding HIPAA (Health Insurandce Portability and Accountability Act)
Department of Health and Human Services Office of the Assistant Secretary for Health (ASH) Advisory Committee on Blood Safety and Availability (ACBSA)
Office of Public Health & Environmental Hazards RETURNING VETERANS WITH HEALTH CONCERNS AND EMERGING PROBLEMS War Related Illness & Injury Study Center.
Managed Care. In the broadest terms, Kongstvedt (1997) describes managed care as a system of healthcare delivery that tries to manage the cost of healthcare,
PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.
Introduction to the Clinical Laboratory
Obtaining Administrative Efficiencies with IT Support Nick FisherBabs Vogelsang Director of Clinical ResearchDirector of Information TechnologySiteman.
Introduction to Healthcare and Public Health in the US The Evolution and Reform of Healthcare in the US Lecture b This material (Comp1_Unit9b) was developed.
HIT FINAL EXAM REVIEW HI120.
1 Copyright © 2011 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 7 Health Care Regulatory and Certifying Agencies.
Accountable Care Organizations: What is the role of the pathologist? What are the public policy implications?
CAHPS PATIENT EXPERIENCE SURVEYS AHRQ ANNUAL MEETING SEPTEMBER 2012 Christine Crofton, PhD CAHPS Project Officer.
Improving Clinical Processes: The Million Hearts ® Hypertension Control Change Package for Clinicians Erica K. Taylor, PhD, MPH, MA Million Hearts ® Minority.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Understanding Clinical Trials – Part 2 Georgianne Arnold, MD Professor of Pediatrics University of Pittsburgh Medical Center Pittsburgh Children’s Hospital.
Regulatory Guidance for Genetic Testing. Three Specific Areas Laboratory tests Results of genetic testing – Clinical – Research GenomeWide Association.
Health Departments and HIV Screening Institute of Medicine Workshop 1: Screening and Access to Care April 15, 2010 Natalie Cramer, Associate Director,
Purposes of NHSN Participation in the NHSN reflects the individual facility’s need for high quality and timely data on adverse events and adherence to.
“Translational research includes two areas of translation. One (T1) is the process of applying discoveries generated during research in the laboratory,
Million Veteran Program Participant Outreach Suma Muralidhar, Ph.D. Million Veteran Program Participant Outreach Suma Muralidhar, Ph.D.
Ethical challenges in research during an epidemic outbreak Krittaecho Siripassorn, MD Chair of the IRB of BIDI Bamrasnaradura Infectious Diseases Institute.
1 HIPAA’s Impact on Depository Financial Institutions 2 nd National Medical Banking Institute Rick Morrison, CEO Remettra, Inc.
GCP (GOOD CLINICAL PRACTISE)
Chapter 33 Introduction to the Nursing Process
Electronic Health Records (EHR)
Cluster Randomized Trials
Cindy Murray NP Princess Margaret Cancer Centre
Thank you to the Congressional Public Health Caucus, which has brought us today to talk about an important issue that affects patient care and treatment,
Research, Experimentation, & Clinical Trials
Component 1: Introduction to Health Care and Public Health in the U.S.
Introduction to Basic Research Methods
Research Operations and Lab Services
Presentation transcript:

The Million Veteran Program: Strategies for Consent & Sample Collection Gerry Higgins, M.D., Ph.D. and the ‘Genomics Advisory Panel’ of OSEHRA

TOPICS 1.Consent and Re-Consent: → Proposed use of a PGP (Personal Genomes Project) Consent Form that has been adopted by NIST’s ‘Genome- in-a-bottle’ program, including the FDA. 2. Obtaining samples for use in a CLIA-accredited laboratory for sequencing. → If it were necessary, could we ‘re-consent’ the ~200K Veterans that have already donated samples without having to re-draw another blood sample? 3. Why the use of a CLIA-accredited laboratory is vital: → The individual Veteran can access his or her own data. → A clinician can use the data for healthcare of the Veteran.

CONSENT AND RE-CONSENT → In the original survey conducted by the Veteran’s Health Administration, participants raked the use of genomic data as the “highest priority for their own healthcare.” → In the various ‘Consent’ forms 1, it was made clear that the data collected would not be used for the individual Veteran’s healthcare, but for larger public health studies. → However, since that time, genome analysis is proving to be of tremendous clinical benefit, and it is anticipated that by the time the MVP finishes data collection, the era of ‘Clinical Genomic Medicine’ will be well underway. 1 All versions of existing MVP consent forms can be found at:

CONSENT AND RE-CONSENT 1. The members of the ‘Genomics Advisory Panel’ recommend that all future sample collections be performed in such a manner to be allow any data collected from an individual Veteran be used for that individual’s healthcare, as well as for larger studies. 2. We recommend that a modified version of the Personal Genomes Project (PGP) consent form, adopted by NIST and the FDA, be used for all future sample collections. 3.We recommend that all future sample collections meet CLIA standards, so that they can be used for the individualized healthcare from the Veteran from which that sample was obtained. 4.If possible, we recommend re-consenting of individual Veterans from which samples have already be collected, in a manner which meets CLIA guidelines, but does not require the re-collection of a blood sample.

The Value of a Modified PGP Consent Form → It ensures that the Veteran signing the Consent Form is completely aware of his or her legal rights. → It explicitly provides a statement about that data collected from that Veteran can be used for that Veteran’s own healthcare. → It provides privacy protection, compliant with HIPAA guidelines. → It has been adopted by federal agencies such as the FDA for participants in clinical trials whose samples will be processed using next generation sequencing.

A view from a Veteran: Rick Williams, J.D., OIF/OEF Veteran (This view is supported by Rick Maguire, Ph.D., a member of the Genomics Advisory Panel, and a former Navy Seal, retired Admiral, who fought in the in the Vietnam era, the First Gulf War, the Second Gulf War and Operation Enduring Freedom. It is also supported by all of the other Veterans who are on the ‘Genomics Advisory Panel’)

CLINICAL LABORATORY IMPROVEMENT ADMENDMENTS (CLIA) → It establishes quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test was performed. → A laboratory is any facility that does laboratory testing on specimens derived from humans to give information for the diagnosis, prevention, treatment of disease, or impairment of, or assessment of health. → The Centers for Medicare & Medicaid Services (CMS) assumes primary responsibility for the CLIA program. → For clinicians who perform next generation sequencing & analysis, it essential that samples be collected & processed following CLIA guidelines.

CLINICAL LABORATORY IMPROVEMENT ADMENDMENTS (CLIA) – THE BIG QUESTIONS FOR THE MVP → Since the initial ~200K samples collected for the Million Veteran Program only contained a single identifier, would it be necessary to obtain another sample for next generation sequencing & analysis? → Or…Is it possible to only have to re-consent those Veterans that have provided samples? → The provisional answer from CMS is that it is not necessary to re-draw blood samples, if the initial samples were collected in a manner that ensures sample tracking, integrity and reproducibility…We need to follow-up on this issue…

END OF PART TWO: